betamethasone sodium phosphate profile

Betamethasone sodium phosphate is a synthetic corticosteroid used in various medical applications, including the treatment of inflammatory conditions like rheumatoid arthritis, eczema, and asthma. It is a potent anti-inflammatory agent that works by suppressing the immune response. Its synthesis involves multiple steps starting from the steroid hormone cortisone, employing various chemical reactions to achieve the desired structure. Betamethasone sodium phosphate is studied extensively due to its therapeutic potential in treating various diseases. Its effectiveness in reducing inflammation and its diverse applications make it an important drug in modern medicine. It is often used in the form of injections, creams, and inhalers. Research continues to explore its therapeutic potential and optimize its use for various conditions.'
```

betamethasone sodium phosphate: phosphate ester of betamethasone; RN given refers to the di-Na salt (11beta,16beta)-isomer; structure in Negwer,5th ed, 4975 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

betamethasone sodium phosphate : An organic sodium salt that is the disodium salt of betamethasone phosphate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	65478
CHEMBL ID	1200762
CHEBI ID	3078
SCHEMBL ID	8418
MeSH ID	M0092825

Synonym
betamethasone 21-disodium phosphate
betamethazone disodium phosphate
nsc-90616
betamethasone sodium phosphate
disodium betamethasone 21-phosphate
AC-2162
betamethasone 21-phosphate disodium
7bk02scl3w ,
unii-7bk02scl3w
beta-methasone disodium phosphate
betamethasone sodium phosphate [usp:jan]
151-73-5
nsc 90616
beta-methasone, disodium phosphate
betamethason sodium phosphate
beta-methasone sodium phosphate
einecs 205-797-0
bentelan
pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methyl-, 21-(dihydrogen phosphate), disodium salt
beta-methasone phosphate
pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, disodium salt, (11beta,16beta)-
celestone phosphate injection
pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-16beta-methyl-, 21-(dihydrogen phosphate), disodium salt
9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-(disodium phosphate)
CHEBI:3078 ,
disodium 9-fluoro-11beta,17-dihydroxy-16beta-methyl-3,20-dioxopregna-1,4-dien-21-yl phosphate
betamethasone 21-phosphate disodium, >=97%
betamethasone sodium phosphate (jp17/usp)
D00972
betamethasone 21-phosphate disodium salt
CHEMBL1200762
cas-151-73-5
tox21_302467
dtxsid8047137 ,
dtxcid6027137
NCGC00256717-01
vista-methasone
betamethasone 21-phosphate sodium salt
betamethasone sodium phosphate [usp monograph]
betamethasone sodium phosphate [who-dd]
betamethasone sodium phosphate [orange book]
betamethasone sodium phosphate [green book]
betamethasone sodium phosphate [mart.]
celestone soluspan component betamethasone sodium phosphate
betamethasone sodium phosphate [usp-rs]
betamethasone sodium phosphate [jan]
pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, disodium salt, (11.beta.,16.beta.)-
betamethasone sodium phosphate component of celestone soluspan
betamethasone sodium phosphate [vandf]
betamethasone sodium phosphate [ep monograph]
betamethasone sodium phosphate [ep impurity]
AKOS015896371
SCHEMBL8418
B4110
mfcd00200361
betamethasone sodium phosphate, european pharmacopoeia (ep) reference standard
betamethasone sodium phosphate, united states pharmacopeia (usp) reference standard
AS-62442
betamethasone sodium phosphate, usp
J-008838
sodium 2-((8s,9r,10s,11s,13s,14s,16s,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl phosphate
disodium;[2-[(8s,9r,10s,11s,13s,14s,16s,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate
PLCQGRYPOISRTQ-LWCNAHDDSA-L
betamethasonesodiumphosphate
Q27105936
betamethasone sodium phosphate (usp:jan)
betamethasone sodium phosphate (ep monograph)
betamethasone sodium phosphate (ep impurity)
betamethasone sodium phosphate (mart.)
betamethasone sodium phosphate (usp-rs)
9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-(disodium phosphate)
betamethasone sodium phosphate (usp monograph)

Excerpt	Reference	Relevance
" Thus, toxic effects can be caused by preservatives or inadequate osmolarity of the vehicles alone."	( Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Arena, JE; Chandler, D; Hida, T; Machemer, R, 1986)	0.27
"To study the pharmacokinetics of different betamethasone doses and preparations used to enhance fetal lung maturation in the maternal and fetal circulation of sheep and the adverse effects on fetal blood pressure."	( Kinetics of betamethasone and fetal cardiovascular adverse effects in pregnant sheep after different doses. Coksaygan, T; Jusko, WJ; Nathanielsz, PW; Samtani, MN; Schwab, M, 2006)	0.33
" Risk-benefit studies are needed to find the effective steroid dose with the least adverse effects."	( Kinetics of betamethasone and fetal cardiovascular adverse effects in pregnant sheep after different doses. Coksaygan, T; Jusko, WJ; Nathanielsz, PW; Samtani, MN; Schwab, M, 2006)	0.33

Excerpt	Reference	Relevance
" Pharmacokinetic evaluation of the data, obtained according to the one-compartment open model, indicated that there were no significant differences between the extent of absorption, and the first-order elimination rate constants."	( Pharmacokinetic evaluation of betamethasone and its water soluble phosphate ester in humans. Brien, R; Jordan, N; Loo, JC; McGilveray, IJ, )	0.13
" We therefore designed a study to capture the true pharmacokinetic profiles of betamethasone from these fast acting and dual-release formulations."	( Betamethasone pharmacokinetics after two prodrug formulations in sheep: implications for antenatal corticosteroid use. Grant, A; Jusko, WJ; Lohle, M; Nathanielsz, PW; Samtani, MN, 2005)	0.33
" The main objectives of the current study were to evaluate the pharmacokinetic and pharmacodynamic features of DFBA when used as an ophthalmic agent, and to compare these features with those of other common ophthalmic agents, to determine which has the highest activity."	( Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. Kida, T; Sakaki, H; Tajika, T; Tsuzuki, M; Waki, M, 2011)	0.37
" However, the pharmacokinetic properties of betamethasone in plasma after intramuscular injection of betamethasone sodium phosphate and betamethasone acetate dual-acting suspension need further investigation."	( Pharmacokinetics of betamethasone after single-dose intramuscular administration of betamethasone phosphate and betamethasone acetate to healthy subjects. Najib, NM; Salem, II, 2012)	0.59
"The main aim of this study was to determine the pharmacokinetic parameters of betamethasone, betamethasone acetate, and betamethasone phosphate after the administration of a single intramuscular dose of the dual-acting suspension to healthy human volunteers."	( Pharmacokinetics of betamethasone after single-dose intramuscular administration of betamethasone phosphate and betamethasone acetate to healthy subjects. Najib, NM; Salem, II, 2012)	0.38
" The plasma samples obtained in the second study were stabilized to enable pharmacokinetic profiling of betamethasone esters."	( Pharmacokinetics of betamethasone after single-dose intramuscular administration of betamethasone phosphate and betamethasone acetate to healthy subjects. Najib, NM; Salem, II, 2012)	0.38
"The observed pharmacokinetic parameters suggested that the acetate ester, and not the phosphate ester, of betamethasone acts as a prodrug or reservoir for betamethasone, conferring on it sustained- and extended-release characteristics."	( Pharmacokinetics of betamethasone after single-dose intramuscular administration of betamethasone phosphate and betamethasone acetate to healthy subjects. Najib, NM; Salem, II, 2012)	0.38
" Plasma data were analyzed using compartmental pharmacokinetic modeling."	( Pharmacokinetics of betamethasone in plasma, urine, and synovial fluid following intra-articular administration to exercised thoroughbred horses. Harrison, LM; Knych, HK; Mckemie, DS; Stanley, SD, 2017)	0.46

Excerpt	Reference	Relevance
" Building on earlier findings, we hypothesized that when administered in combination with slow-release betamethasone acetate, betamethasone phosphate and the high maternal-fetal betamethasone concentrations it generates are redundant for fetal lung maturation."	( Betamethasone phosphate reduces the efficacy of antenatal steroid therapy and is associated with lower birthweights when administered to pregnant sheep in combination with betamethasone acetate. Carter, S; Fee, EL; Furfaro, L; Jobe, AH; Kemp, MW; Newnham, JP; Saito, M; Schmidt, AF; Takahashi, T; Takahashi, Y; Usuda, H; Yaegashi, N, 2022)	0.72

Excerpt	Reference	Relevance
" Bioavailability of betamethasone from the phosphate ester was as high as after intravenous injection."	( Disposition of betamethasone in parturient women after intramuscular administration. Ashley, JJ; McBride, WG; Nation, RL; Petersen, MC, 1984)	0.27
"The main aim of the present work was to formulate and evaluate hydrogel-based drug delivery containing combination of neomycin sulphate and betamethasone sodium phosphate in order to provide prolonged release and also better bioavailability of drugs for the treatment of eye infections."	( Novel hydrogel-based ocular drug delivery system for the treatment of conjunctivitis. Deepthi, S; Jose, J, 2019)	0.72
"Oral Dex-P had lower bioavailability than Beta-P, giving a lower maximum maternal and fetal concentration."	( Oral antenatal corticosteroids evaluated in fetal sheep. Bridges, JP; Clarke, M; Fee, EL; Jobe, AH; Kannan, PS; Kemp, MW; Kumagai, Y; Newnham, JP; Saito, M; Schmidt, AF; Usuda, H, 2019)	0.51

Excerpt	Relevance	Reference
" Quantitation is described for betamethasone sodium phosphate in dosage forms in the presence of polar excipients."	( Analysis of steroid phosphates by high-pressure liquid chromatography: betamethasone sodium phosphate. Sancilio, FD; Townley, ER; Upton, LM, 1978)	0.78
"An intravenous bolus of betamethasone, at an approximate dosage of 3 mg/kg, was administered to 20 patients with septic shock."	( Betamethasone sodium phosphate injection: high-dose regimen in septic shock. Lederer, V, 1984)	1.71
" It was evaluated in a group of 18 normal subjects to determine whether it exerted any systemic glucocorticoid activity after single oral or intrarectal doses and after short-term dosing by the intranasal route."	( Tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application. Bolte, E; Du Souich, P; Goyer, R; Larochelle, P; Lelorier, J, 1983)	0.27
" Plasma concentrations of betamethasone reached a peak 5-37 min after dosing with betamethasone phosphate, then declined biexponentially with a mean terminal half-life of 262 min."	( Disposition of betamethasone in parturient women after intravenous administration. Ashley, JJ; Collier, CB; McBride, WG; Nation, RL; Petersen, MC, 1983)	0.27
" The dosage was 50 microg two dose unit sprays and BSP 500 microg, each 4 times daily."	( Fluticasone propionate spray and betamethasone sodium phosphate mouthrinse: a randomized crossover study for the treatment of symptomatic oral lichen planus. Hegarty, AM; Hodgson, TA; Lewsey, JD; Porter, SR, 2002)	0.6
"Antenatal corticotherapy is responsible for two different phases of fetal heart rate modifications that do not vary according to the corticosteroid or the dosage regimen."	( Immediate and delayed effects of antenatal corticosteroids on fetal heart rate: a randomized trial that compares betamethasone acetate and phosphate, betamethasone phosphate, and dexamethasone. Devos, P; Leclerc, G; Puech, F; Subtil, D; Therby, D; Tiberghien, P; Vaast, P, 2003)	0.32
" In light of this newly identified long terminal half-life for the betamethasone dual formulation, dosing practices for betamethasone in pregnancy need to be reassessed."	( Betamethasone pharmacokinetics after two prodrug formulations in sheep: implications for antenatal corticosteroid use. Grant, A; Jusko, WJ; Lohle, M; Nathanielsz, PW; Samtani, MN, 2005)	0.33
"Beta-PO4 alone is ineffective with the dosing schedule used; Beta-Ac can induce lung maturation."	( Betamethasone for lung maturation: testing dose and formulation in fetal sheep. Ikegami, M; Jobe, AH; Kallapur, SG; Moss, TJ; Newnham, JP; Nitsos, I, 2007)	0.34
" Using this information, we calculated dose-response curves, IC(50) values, and K(d) values to evaluate each drug's K(i) value."	( Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. Kida, T; Sakaki, H; Tajika, T; Tsuzuki, M; Waki, M, 2011)	0.37
"Antenatal steroids are standard of care for women who are at risk of preterm delivery; however, antenatal steroid dosing and formulation have not been evaluated adequately."	( Low-dose betamethasone-acetate for fetal lung maturation in preterm sheep. Furfaro, L; Jobe, AH; Kallapur, SG; Kannan, PS; Kemp, MW; Kramer, BW; Newnham, JP; Rittenschober-Böhm, J; Saito, M; Schmidt, AF; Stock, S; Usuda, H; Watanabe, S, 2018)	0.48
" Antenatal corticosteroid dosing regimens remain unoptimized and without maternal weight-adjusted dosing."	( The efficacy of antenatal steroid therapy is dependent on the duration of low-concentration fetal exposure: evidence from a sheep model of pregnancy. Clarke, M; Eddershaw, PJ; Furfaro, L; Hanita, T; Ireland, D; Jobe, AH; Kemp, MW; Kumagai, Y; Molloy, TJ; Musk, GC; Newnham, JP; Payne, MS; Saito, M; Sato, S; Schmidt, A; Usuda, H; Watanabe, S, 2018)	0.48
" These findings underscore the need to develop an optimized steroid dosing regimen that may improve both the efficacy and safety of antenatal corticosteroids therapy."	( The efficacy of antenatal steroid therapy is dependent on the duration of low-concentration fetal exposure: evidence from a sheep model of pregnancy. Clarke, M; Eddershaw, PJ; Furfaro, L; Hanita, T; Ireland, D; Jobe, AH; Kemp, MW; Kumagai, Y; Molloy, TJ; Musk, GC; Newnham, JP; Payne, MS; Saito, M; Sato, S; Schmidt, A; Usuda, H; Watanabe, S, 2018)	0.48
"Conventional dosage form like eye drops showed poor therapeutic response and also require frequent dosing."	( Novel hydrogel-based ocular drug delivery system for the treatment of conjunctivitis. Deepthi, S; Jose, J, 2019)	0.51
" We report the pharmacokinetics and pharmacodynamics of oral dosing of ACS using a preterm sheep model."	( Oral antenatal corticosteroids evaluated in fetal sheep. Bridges, JP; Clarke, M; Fee, EL; Jobe, AH; Kannan, PS; Kemp, MW; Kumagai, Y; Newnham, JP; Saito, M; Schmidt, AF; Usuda, H, 2019)	0.51
"Using a sheep model, we demonstrate the use of pharmacokinetics to develop oral dosing strategies for ACS."	( Oral antenatal corticosteroids evaluated in fetal sheep. Bridges, JP; Clarke, M; Fee, EL; Jobe, AH; Kannan, PS; Kemp, MW; Kumagai, Y; Newnham, JP; Saito, M; Schmidt, AF; Usuda, H, 2019)	0.51
" Antenatal corticosteroid dosing remains nonoptimized, and there is little understanding of how different treatment-to-delivery intervals may affect treatment efficacy."	( The duration of fetal antenatal steroid exposure determines the durability of preterm ovine lung maturation. Bridges, J; Eddershaw, PJ; Fee, EL; Furfaro, L; Hanita, T; Jobe, AH; Kemp, MW; Kumagai, Y; Musk, GC; Newnham, JP; Payne, MS; Saito, M; Sato, S; Schmidt, AF; Smallwood, K; Stinson, L; Takahashi, T; Usuda, H; Watanabe, S, 2020)	0.56
" First, we performed pharmacokinetic studies in non-pregnant monkeys to compare blood levels of the steroids using oral dosing with Beta-P, Dex-P and an effective maternal intramuscular dose of the beta-acetate component of the clinical treatment."	( Oral dosing for antenatal corticosteroids in the Rhesus macaque. Bridges, JP; Clarke, MW; Jobe, AH; Kannan, PS; Kemp, MW; Milad, M; Miller, LA; Schmidt, AF, 2019)	0.51
" Trying to take into account both efficacy and safety, we simulated different dosing schemes in order to maintain a maximum of fetuses above 1 ng/mL without exceeding the total standard dose."	( Maternal Betamethasone for Prevention of Respiratory Distress Syndrome in Neonates: Population Pharmacokinetic and Pharmacodynamic Approach. Benaboud, S; Bouazza, N; Foissac, F; Goffinet, F; Hirt, D; Jarreau, PH; Kayem, G; Lui, G; Mandelbrot, L; Rozenberg, P; Tréluyer, JM; Ville, Y; Zheng, Y, 2020)	0.56
" There is a marked variation in antenatal steroid dosing strategy, selection for treatment criteria, and agent choice worldwide."	( Variability in the efficacy of a standardized antenatal steroid treatment was independent of maternal or fetal plasma drug levels: evidence from a sheep model of pregnancy. Carter, S; Clarke, M; Fee, EL; Hanita, T; Ikeda, H; Jobe, AH; Kemp, MW; Koshinami, S; Kumagai, Y; Newnham, JP; Saito, M; Sato, S; Schmidt, AF; Takahashi, T; Takahashi, Y; Usuda, H; Watanabe, S; Yaegashi, N, 2020)	0.56
" However, the optimal (maximum benefit and minimal risk of side effects) antenatal corticosteroid dosing strategy remains unclear."	( Betamethasone phosphate reduces the efficacy of antenatal steroid therapy and is associated with lower birthweights when administered to pregnant sheep in combination with betamethasone acetate. Carter, S; Fee, EL; Furfaro, L; Jobe, AH; Kemp, MW; Newnham, JP; Saito, M; Schmidt, AF; Takahashi, T; Takahashi, Y; Usuda, H; Yaegashi, N, 2022)	0.72
"Using an established sheep model of prematurity and postnatal ventilation of the preterm lamb, we aimed to compare the pharmacodynamic effects of low-dosage treatment with betamethasone acetate only against a standard dosage of betamethasone phosphate and betamethasone acetate as recommended by the American College of Obstetricians and Gynecologists for women at risk of imminent preterm delivery between 24 0/7 and 35 6/7 weeks' gestation."	( Betamethasone phosphate reduces the efficacy of antenatal steroid therapy and is associated with lower birthweights when administered to pregnant sheep in combination with betamethasone acetate. Carter, S; Fee, EL; Furfaro, L; Jobe, AH; Kemp, MW; Newnham, JP; Saito, M; Schmidt, AF; Takahashi, T; Takahashi, Y; Usuda, H; Yaegashi, N, 2022)	0.72

Class	Description
organic sodium salt
tertiary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
GLI family zinc finger 3	Homo sapiens (human)	Potency	0.0035	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	0.0078	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID1259381; AID743036; AID743040; AID743042; AID743053; AID743054
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.0237	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	48.9363	0.0015	30.6073	15,848.9004	AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptor	Homo sapiens (human)	Potency	44.1967	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	0.4426	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743078; AID743080; AID743091
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	50.0381	0.0010	19.4141	70.9645	AID743191
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	62.4295	0.0007	23.0674	1,258.9301	AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	0.2485	0.0017	23.8393	78.1014	AID743083
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	24.8536	0.0003	23.4451	159.6830	AID743065
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	0.8818	0.0015	57.7890	15,848.9004	AID1259244
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	0.8818	0.0015	51.7393	15,848.9004	AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	38 (23.17)	18.7374
1990's	20 (12.20)	18.2507
2000's	57 (34.76)	29.6817
2010's	37 (22.56)	24.3611
2020's	12 (7.32)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	33 (17.93%)	5.53%
Reviews	5 (2.72%)	6.00%
Case Studies	34 (18.48%)	4.05%
Observational	0 (0.00%)	0.25%
Other	112 (60.87%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (110)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 1, Open-Label, Randomized Study to Compare the Pharmacokinetics and Pharmacodynamics of Single Dose Dexamethasone and Betamethasone Administered Orally and Intramuscularly in Healthy Female Subjects [NCT03668860]	Phase 1	48 participants (Actual)	Interventional	2018-09-20	Completed
Single Dose Antenatal Corticosteroids (SNACS) Pilot Randomized Control Trial for Women at Risk of Preterm Birth [NCT04494529]	Phase 3	30 participants (Actual)	Interventional	2021-03-01	Completed
A Phase 2a Trial Evaluating the Anti-psoriatic Effect of LP0113 Aerosol Spray Compared With Its Vehicle and With Daivobet® Gel, LEO 90100 Aerosol Foam, Betamethasone Dipropionate Aerosol Spray and Calcipotriol Aerosol Spray in the Treatment of Psoriasis V [NCT02416258]	Phase 2	50 participants (Actual)	Interventional	2015-04-30	Completed
An Investigator Initiated Study Evaluating the Efficacy and Tolerability of Enstilar Foam (Calcipotriene and Betamethasone Dipropionate) in Patients With Nail Psoriasis [NCT04227288]	Phase 4	3 participants (Actual)	Interventional	2021-11-01	Completed
Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study [NCT03707795]	Early Phase 1	6 participants (Actual)	Interventional	2017-08-21	Completed
Study Role of the Local Treatments on the Microbiome Modulation in the Psoriatic Skin. Study Monocentric, Interventional, Randomized and Single-blind [NCT03584360]	Phase 2	30 participants (Actual)	Interventional	2018-09-24	Completed
A Comparative Study of Betamethasone (Diprospan) and Triamcinolone Acetonide as Single Intra-Articular Injection in Knee Osteoarthritis, A Double-Blinded, Randomized Controlled Trial [NCT05139875]	Phase 4	120 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Crossover Study to Evaluate the Comparative Bioavailability, Pharmacokinetics, and Safety of GTX-102 Administered as an Oral Spray Compared to Intramuscular Injection and an Oral Solution of Betamethasone in Healthy Subjects [NCT05531890]	Phase 1	48 participants (Actual)	Interventional	2022-09-13	Active, not recruiting
A Phase 1b, Randomised, Controlled, Observer-blinded Trial to Assess Safety, Tolerability and Pharmacodynamic Effects of LEO 134310 Cutaneous Solution in Descaled Skin of Adults With Chronic Plaque Psoriasis [NCT03669757]	Phase 1	13 participants (Actual)	Interventional	2018-09-27	Completed
Effect of Antenatal Corticosteroids on Neonatal Morbidity. [NCT03446937]		150 participants (Actual)	Interventional	2017-12-01	Completed
Phase II Study of Navigator vs Standard Needle Injection for Hip [NCT02066844]	Phase 2	40 participants (Actual)	Interventional	2014-02-28	Completed
Therapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis. [NCT03054610]	Phase 1	60 participants (Actual)	Interventional	2015-01-31	Completed
A Multicentre Study Evaluating the Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Standard of Care in the Treatment of Severe Atopic Dermatitis, a Phase II Randomized, Clinical Trial [NCT03052348]		78 participants (Anticipated)	Interventional	2017-11-01	Not yet recruiting
Effects of Antenatal Corticosteroid in Twin Neonates With Late Preterm Birth: Study Protocol for a Randomized Controlled Trial [NCT03547791]	Phase 2/Phase 3	808 participants (Anticipated)	Interventional	2018-05-05	Recruiting
Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study Comparing Taro Product to RLD and Both Active Treatments to a Placebo Control in the Treatment of Scalp Psoriasis [NCT03880357]	Phase 1	485 participants (Actual)	Interventional	2018-10-22	Completed
Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis [NCT03441789]	Phase 4	28 participants (Actual)	Interventional	2017-09-18	Completed
Validation of a Novel Composite of Skin Biomarkers as a Primary Outcome Measure for Evaluating the Safety of Treatments for Atopic Dermatitis: a Randomized Controlled Trial (Phase 2) Comparing the Effects of Crisaborole 2% Ointment to Betamethasone Valera [NCT04194814]	Phase 2	37 participants (Actual)	Interventional	2020-11-20	Completed
A 28-day, Double-blind, Randomized, Reference-controlled Open Psoriasis Plaque Test for Within Subject Comparison of Efficacy and Safety of Mapracorat 0.1% Ointment and 4 Reference Products in Symptomatic Volunteers With Stable Plaque-type Psoriasis [NCT03399526]	Phase 1	24 participants (Actual)	Interventional	2013-02-11	Completed
A Phase 1b, Randomised, Controlled, Assessor-blinded Proof of Principle Trial to Assess Safety, Tolerability and Pharmacodynamics Effects of Microarray Patches Containing Calcipotriol/Betamethasone Dipropionate in Descaled Skin of Adults With Chronic Plaq [NCT03898583]	Phase 1	15 participants (Actual)	Interventional	2019-04-15	Completed
Phototherpy Versus Tap Water Iontophoresis for Management of Atopic Dermatitis in Children, Randomized Clinical Trial. [NCT04444726]		60 participants (Actual)	Interventional	2019-01-20	Completed
Comparison of Nigella Sativa Oil With Conventional Management on Clinical Outcomes in Oral Submucous Fibrosis [NCT04476420]	Phase 3	39 participants (Actual)	Interventional	2021-02-11	Completed
Real-life Evaluation of an Applicator, as a New Mode of Administration of Daivobet® Gel, on Adherence to Treatment and SAtisfaction of Patients With PSOriasis [NCT02856542]		1,560 participants (Actual)	Observational	2016-05-23	Completed
Bioequivalence of Two Augmented Betamethasone Dipropionate 0.05% Topical Creams [NCT00800293]		116 participants (Actual)	Observational	2002-12-31	Completed
Multi-center,Single Blind, Parallel-Controlled Study of the Efficacy and Safety of Calcipotriol Betamethasone Ointment Plus Calcipotriol Ointment in Sequential Therapy to Psoriasis Vulgaris [NCT02191007]		230 participants (Actual)	Interventional	2013-11-30	Completed
Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis [NCT04976816]	Phase 2/Phase 3	92 participants (Actual)	Interventional	2021-12-01	Completed
A Comparative Clinical and Immunohistochemical Study Between Topical Pimecrolimus and Corticosteroid in Treatment of Oral Lichen Planus [NCT02443311]	Phase 4	24 participants (Actual)	Interventional	2010-09-30	Completed
Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata: a Clinical and Dermoscopic Study. [NCT06087796]	Phase 1	60 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis [NCT01011621]	Phase 3	170 participants (Anticipated)	Interventional	2010-02-28	Not yet recruiting
Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth: a Randomized, Multicentre, Double Blind Placebo-controlled Non Inferiority Trial [NCT02897076]	Phase 3	3,250 participants (Actual)	Interventional	2017-01-31	Completed
A Phase Ib, Multi-Center, Randomized, Vehicle- and Comparator-Controlled Trial, Double-Blind for the Investigational Medicinal Products, Observer-Blind for the Comparators to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque [NCT04221906]	Phase 1	15 participants (Actual)	Interventional	2020-01-06	Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd) to [NCT03731091]	Phase 3	494 participants (Actual)	Interventional	2018-10-31	Completed
Managment of Refractory Cases of Chronic Non Bacterial Prostatitis by TRUS Guided Injection of Betamethason [NCT04210739]	Early Phase 1	20 participants (Anticipated)	Interventional	2020-07-31	Not yet recruiting
A Phase I, Randomized, Observer-blind, Single-center, Vehicle- And Comparator-controlled, Initial Dose-ranging Study To Assess The Antipsoriatic Efficacy Of Different Concentrations Of An2728 Ointment In A Psoriasis Plaque Test [NCT00762658]	Phase 1	12 participants (Actual)	Interventional	2007-11-30	Completed
A Phase I, Randomized, Observer-blind, Single-center, Vehicle- And Comparator-controlled, Initial Dose-ranging Study To Assess The Antipsoriatic Efficacy Of Different Concentrations Of An2728 Cream In A Psoriasis Plaque Test [NCT00763204]	Phase 1	12 participants (Actual)	Interventional	2008-02-29	Completed
A Double-Blind, Vehicle-Controlled, Rising Dose, Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis [NCT00820950]	Phase 2	29 participants (Actual)	Interventional	2007-05-31	Completed
Xamiol® Gel in BODY Psoriasis : lonG-term Management of Psoriasis vUlgARis With Xamiol® Gel in Daily Clinical Practice of Russian Dermatologists. A Long-term Observational, Prospective Study [NCT02636101]		603 participants (Actual)	Observational	2016-01-31	Completed
Pimecrolimus 1% Cream vs. Betamethasone Valerate 0.1% Cream in the Treatment of Facial Discoid Lupus Erythematosus: a Double-Blind Randomized, Pilot Study. [NCT00608673]		10 participants (Actual)	Interventional	2006-04-30	Completed
Evaluation of Topical Rebamipide Versus Topical Betamethasone for Management of Oral Ulcers in Behcet's Disease: A Randomized Clinical Trial [NCT06084624]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Topical Cetirizine Versus Topical Betamethasone in Treatment of Localized Alopecia Areata [NCT05803070]		59 participants (Anticipated)	Observational	2023-09-01	Not yet recruiting
[NCT00914836]		0 participants (Actual)	Interventional	2009-06-30	Withdrawn(stopped due to difficulties in the department)
Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies : a Multicentre Randomized Controlled Trial [NCT02586961]	Phase 2/Phase 3	195 participants (Actual)	Interventional	2015-10-31	Terminated(stopped due to Removal of Adrénaline lots for safety reasons.)
One-year Prospective, Observational Study of the Journey of Patients With Plaque Psoriasis Prescribed Calcipotriol/Betamethasone Aerosol Foam or Other Topical Therapy [NCT02935582]		1,214 participants (Actual)	Observational	2017-01-31	Completed
A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Cervical and Thoracic Interlaminar Epidural Injections in Thoracic and Cervical Disc Herniation, Discogenic Pain, and Post-Cervical Laminectomy Syndrome [NCT01071369]	Phase 4	120 participants (Actual)	Interventional	2008-02-29	Completed
Evaluation of Efficacy and Safety of Epidural Steroid Injection Using Dexamethasone or Betamethasone in Patients With Spinal Pain: a Prospective, Randomized, Double-blind Study [NCT01885481]		600 participants (Actual)	Interventional	2013-10-31	Completed
A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disea [NCT04734210]	Phase 2	139 participants (Actual)	Interventional	2021-01-07	Completed
[NCT01946386]	Phase 1	35 participants (Actual)	Interventional	2013-09-30	Completed
Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle, and the Gel Vehicle Alone in Scalp Psoriasis [NCT00216827]	Phase 3	1,485 participants	Interventional	2004-11-30	Completed
Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) [NCT04593706]		40 participants (Anticipated)	Interventional	2020-11-01	Not yet recruiting
Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris [NCT02004574]	Phase 4	201 participants (Actual)	Interventional	2013-10-31	Completed
Investigation of the Effect of Central Sensitization on Steroid Injection Response in Patients With Shoulder Pain Secondary to Rotator Cuff Lesion [NCT05926895]		36 participants (Anticipated)	Interventional	2023-06-02	Recruiting
Comparison Between Subacromial Ultrasound Guided and Systemic Steroid Injection for Frozen Shoulder: a Randomized Double Blind Study [NCT04931511]	Phase 4	20 participants (Actual)	Interventional	2021-06-01	Terminated(stopped due to Since the COVID-19 pendemic, the regular follow-up of participant became very hard. The participant were not willing to go back to the hospital for repeat measurement. So we stop the study and plan to redesign the protocol.)
The Maintenance Effect of Enstilar Foam in Combination With Otezla [NCT04555707]	Phase 4	30 participants (Anticipated)	Interventional	2020-06-24	Recruiting
A Double-Blind, Within-Subject Randomised, Placebo-Controlled, Proof of Concept, Comparison Study of SHP-141C Topical Cream in Psoriasis, Using the Microplaque Assay. [NCT01646567]	Phase 1	14 participants (Actual)	Interventional	2012-09-30	Completed
The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover [NCT04114097]	Phase 4	36 participants (Actual)	Interventional	2019-08-22	Completed
A Phase I Trial to Evaluate Safety and Efficacy of Topically Applied GSK2981278 Ointment in a Psoriasis Plaque Test [NCT02548052]	Phase 1	15 participants (Actual)	Interventional	2015-10-22	Completed
Prospective, Observational, Non-interventional, Multicenter Study on the Efficacy and Tolerability of Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients With Plaque Psoriasis Under Daily Practice Conditions [NCT02881346]		410 participants (Actual)	Observational	2016-09-30	Completed
A Randomized, Multicenter, Sham Controlled, Double-Masked, Phase 2/3 Study Assessing Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema [NCT01411254]	Phase 2/Phase 3	0 participants	Interventional		Completed
Nickel Desensitization Using Topical Therapy [NCT01413477]		24 participants (Anticipated)	Interventional	2011-08-31	Not yet recruiting
Phase 3 Study, Randomized, Double-blind, Parallel to Evaluate Ketoconazole and Betamethasone Dipropionate(Candicort®) Compared to Clotrimazole and Dexamethasone Acetate(Baycuten N®) in Relief of Fungal Infections/Dermatophytosis Symptoms. [NCT02582177]	Phase 3	125 participants (Actual)	Interventional	2019-06-11	Completed
A Multi Centre, Parallel, Randomised Study of the Skin Tolerance of Betamethasone Creams on Atopic Eczema and the Influence of Moisturiser Treatment on the Recurrence of Eczema [NCT00576238]	Phase 3	55 participants (Actual)	Interventional	2004-01-31	Completed
A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema [NCT00576550]	Phase 4	53 participants (Actual)	Interventional	2007-10-31	Completed
Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle and Calcipotriol in the Gel Vehicle in Scalp Psoriasis [NCT00216840]	Phase 3	1,350 participants	Interventional	2004-12-31	Completed
Long-term Treatment of Scalp Psoriasis With Calcipotriol Plus Betamethasone Dipropionate Gel [NCT00216879]	Phase 3	800 participants	Interventional	2005-02-28	Completed
Nonaromatic Naphthalan - Composition Study and Biological Effects on Epithelial Tissues [NCT02920658]	Phase 2	57 participants (Actual)	Interventional	2010-12-31	Completed
A Psoriasis Plaque Test Comparing LEO 29102 Cream and Its Different Combinations to Daivobet® Ointment and a Vehicle Control for the Treatment of Psoriasis Vulgaris [NCT00875277]	Phase 2	24 participants (Actual)	Interventional	2009-04-30	Completed
Observational and Prospective Study in Patients With Nail Psoriasis Treated With Calcipotriene and Betamethasone Dipropionate Aerosol Foam to Evaluate the Change in the Severity of Psoriasis and in the Quality of Life [NCT04380597]		10 participants (Actual)	Observational	2019-03-26	Completed
Efficacy and Safety of add-on Topical Timolol in the Management of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-induced Paronychia: A Prospective Randomized Open-labelled Trial [NCT06140186]	Phase 3	40 participants (Anticipated)	Interventional	2023-04-01	Recruiting
A Randomized, Sham Controlled, Multicenter, Double-Masked, Phase 2/3 Study Assessing Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion [NCT01512901]	Phase 2/Phase 3	0 participants	Interventional		Completed
A Randomized, Evaluator Blinded, Within Subject, Single-Centre Evaluation of the Vasoconstriction Properties of MC2-01 Cream, Compared to 5 Other Corticosteroids in Healthy Subjects [NCT03758365]	Phase 1	36 participants (Actual)	Interventional	2018-11-05	Completed
Double-blind Evaluation of the Safety and Efficacy of Quadriderme® (Betamethasone Diproprionate, Clotrimazole and Gentamicin) Compared With Betamethasone Diproprionate Combined With Gentamicin Sulfate and With Betamethasone Diproprionate in the Treatment [NCT00671528]	Phase 4	3 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to terminated early due to lack of recruitment [only 3 of 207 subjects were enrolled])
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris [NCT00817219]	Phase 2	33 participants (Actual)	Interventional	2009-07-31	Completed
Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle and the Gel Vehicle Alone in Psoriasis Vulgaris [NCT00263718]	Phase 2	360 participants	Interventional	2005-12-31	Completed
Calcipotriol Plus Betamethasone Dipropionate Gel Compared to DAIVONEX/DOVONEX Scalp Solution in Patients With Scalp Psoriasis [NCT00243464]	Phase 3	300 participants	Interventional	2005-09-30	Completed
A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris [NCT00248456]	Phase 4	320 participants	Interventional	2005-10-31	Completed
[NCT00418353]		0 participants	Interventional	2002-08-31	Completed
Single Dose of Antenatal Corticosteroids (SNACS) Randomized Controlled Trial for Pregnancies at Risk of Preterm Delivery: To Keep Babies and Children Safe [NCT05114096]	Phase 4	3,254 participants (Anticipated)	Interventional	2023-07-20	Recruiting
A Randomized Phase III, Three-parallel Arm, Assessor Blind, Multi-centre Study to Evaluate the Efficacy, Safety and Tolerability of AKP02 Cutaneous Spray Versus Enstilar Cutaneous Foam in Subjects With Mild to Moderate Psoriasis. [NCT05249972]	Phase 3	294 participants (Anticipated)	Interventional	2022-01-24	Recruiting
Efficacy and Safety of LEO 90105 Ointment (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris [NCT01422434]	Phase 3	676 participants (Actual)	Interventional	2011-07-31	Completed
[NCT01536938]	Phase 2	303 participants (Actual)	Interventional	2012-05-31	Completed
The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients [NCT03848871]	Phase 4	20 participants (Actual)	Interventional	2017-12-12	Completed
A Phase 1 Randomized, Placebo and Active Comparator-controlled Trial, Double-blind for the IPs, Observer-blind for the Active Comparator, to Assess the Potency of SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment in a Psoriasis Plaque Test [NCT03004339]	Phase 1	13 participants (Actual)	Interventional	2016-08-31	Completed
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris [NCT01707043]	Phase 4	20 participants (Actual)	Interventional	2012-10-31	Completed
A Comparative Study Between Topical Betamethasone Cream or Topical Olive Oil Cream in Prophylaxis Against Acute Radiodermatitis in Breast Cancer Patients. [NCT05285943]	Phase 4	132 participants (Anticipated)	Interventional	2021-11-04	Recruiting
A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris [NCT01347255]	Phase 2	24 participants (Actual)	Interventional	2011-05-31	Completed
An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis [NCT00437255]	Phase 4	122 participants (Actual)	Interventional	2006-08-31	Completed
Timing of Late Preterm Corticosteroid Administration and Neonatal Hypoglycemia [NCT04869709]	Phase 4	210 participants (Anticipated)	Interventional	2021-07-31	Not yet recruiting
The Impact of Stress on Fetal Brain Development [NCT03831126]		24 participants (Anticipated)	Observational	2019-02-01	Recruiting
A Phase 3 Study Comparing Once Daily Treatment With Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension With Betamethasone 0.5 mg/g (as Dipropionate) in the Topical Suspension Vehicle, Calcipotriol 50 mcg/g in the Topica [NCT01188928]	Phase 3	1,152 participants (Actual)	Interventional	2010-09-30	Completed
The Effect of Betamethasone Dipropionate on Patients With Eosinophilic Chronic Rhinosinusitis [NCT05220293]	Phase 1/Phase 2	12 participants (Anticipated)	Interventional	2022-02-23	Recruiting
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease [NCT04734197]	Phase 2	351 participants (Actual)	Interventional	2021-01-11	Completed
A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Caudal Epidural Injections in Lumbar Disc Herniations, Spinal Stenosis, Discogenic Pain, and Post-Lumbar Laminectomy Syndrome [NCT00370799]	Early Phase 1	240 participants (Actual)	Interventional	2007-01-31	Completed
Comparison of the Efficacy Between Transforaminal Steroid Epidural Injection and Epidural Neuroplasty for the Treatment of Herniated Lumbar Disc：A Single Center, Controlled Clinical Trial [NCT03101033]		92 participants (Actual)	Interventional	2015-05-31	Completed
Can an App Supporting Psoriasis Patients Improve Adherence to Topical Treatment? A Single-blind Randomized Controlled Trial [NCT02858713]	Phase 4	134 participants (Actual)	Interventional	2017-01-09	Completed
Single-site, Double Blinded, Randomized Investigation of Corticosteroid Versus Placebo Injection Under Ultrasound Guidance in Patients With Syndesmotic Ligament Injury or High Ankle Sprain [NCT02892500]	Phase 2	1 participants (Actual)	Interventional	2016-04-30	Terminated(stopped due to Inability to enroll subjects)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Lt [NCT03331523]	Phase 3	643 participants (Actual)	Interventional	2017-10-20	Completed
Non-surgical Treatment of Carpal Tunnel Syndrome: Night Splint Versus Local Corticosteroid Infiltration: Clinical Randomized Trial [NCT03196817]	Phase 4	84 participants (Actual)	Interventional	2016-08-01	Active, not recruiting
An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults With Mild to Moderate Atopic Dermatitis [NCT02376049]	Phase 1	30 participants (Actual)	Interventional	2015-02-28	Completed
Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance [NCT05058209]	Phase 4	20 participants (Actual)	Interventional	2020-11-30	Completed
The Effect of Intra-sinus Application of Betamethasone Dipropionate Nasal Cream on Patients With Chronic Rhinosinusitis Post Functional Endoscopic Sinus Surgery (FESS) [NCT05882903]	Phase 2	12 participants (Anticipated)	Interventional	2023-08-17	Recruiting
Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) [NCT05981118]		40 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study [NCT04207931]	Phase 4	250 participants (Anticipated)	Interventional	2018-04-30	Recruiting
A Comparative Study on Clinical Efficacy of Clobetasol and Betamethasone in Orabase in Combination With Clotrimazole, in Oral Lichen Planus [NCT03026478]	Phase 2	30 participants (Anticipated)	Interventional	2016-05-06	Recruiting
A Single-Centre, Explorative, Randomised, Investigator-Blinded, Negative-Controlled, Phase I Clinical Trial With Intra-Individual Comparison of Treatments to Assess Steroid Induced Skin Atrophy on Healthy Skin [NCT02355639]	Phase 1	16 participants (Actual)	Interventional	2015-01-31	Completed
An Open-Label, Multicenter Study of Patient-Reported Satisfaction Following Twice Daily Dosing With Betamethasone Dipropionate Spray, 0.05% in Subjects With Moderate Plaque Psoriasis [NCT02749799]	Phase 4	45 participants (Actual)	Interventional	2016-02-29	Completed
A Randomized, Double-Blind Study Comparing TOLMAR Calcipotriene and Betamethasone Suspension to Reference Listed Drug in the Treatment of Scalp Psoriasis [NCT03122353]	Phase 1	699 participants (Actual)	Interventional	2017-04-11	Completed
Efficacy of Excimer Laser Combined With Either Topical Tazarotene or Topical Betamethasone Valerate Versus Excimer Laser Alone in Treatment of Localized Chronic Plaque Psoriasis; Clinical and Dermoscopic Study [NCT05555797]	Phase 4	30 participants (Anticipated)	Interventional	2022-10-30	Not yet recruiting
Calcipotriol /Betamethasone Ointment Versus Fractional CO2 Laser Plus Calcipotriol /Betamethasone Ointment in the Treatment of Plaque Psoriasis: Randomized Comparative Study [NCT06011083]		40 participants (Actual)	Interventional	2022-08-01	Completed
Biologics and Blistering - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Through Suction Blistering [NCT05535738]	Phase 2/Phase 3	45 participants (Anticipated)	Interventional	2022-11-15	Recruiting
A Study to Investigate the Irritation Potential on Healthy Intact Skin and Effect on Psoriatic Skin of Topical Applications of GW786034 [NCT00358384]	Phase 1	10 participants (Actual)	Interventional	2005-09-26	Completed
Betamethasone (Betapred®) as Premedication for Reducing Postoperative Vomiting and Pain After Tonsillectomy - a Randomized, Double-blind, Placebo-controlled Trial [NCT03783182]	Phase 4	100 participants (Anticipated)	Interventional	2019-09-10	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00671528 (1) [back to overview]	Number of Days Required to Achieve Total Remission
NCT00817219 (10) [back to overview]	"Controlled Disease(i.e., Clear or Almost Clear) According to the Investigator's Global Assessment of Disease Severity at Week 4."
NCT00817219 (10) [back to overview]	"Controlled Disease(i.e., Clear or Very Mild) According to the Patient's Global Assessment of Disease Severity at Week 4."
NCT00817219 (10) [back to overview]	Adverse Drug Reactions
NCT00817219 (10) [back to overview]	Change in Albumin Corrected Serum Calcium From Baseline to End of Treatment
NCT00817219 (10) [back to overview]	Serum Cortisol Concentration of ≤18 mcg/dL at 30 Minutes After ACTH-challenge at End of Treatment
NCT00817219 (10) [back to overview]	Change in Urinary Calcium:Creatinine Ratio From Baseline to End of Treatment.
NCT00817219 (10) [back to overview]	PASI 50 at Week 4.
NCT00817219 (10) [back to overview]	PASI 75 at Week 4.
NCT00817219 (10) [back to overview]	Percentage Change in PASI From Baseline to Week 4.
NCT00817219 (10) [back to overview]	Serum Cortisol Concentration of ≤18 mcg/dL at 30 and 60 Minutes After ACTH-challenge at End of Treatment
NCT00820950 (6) [back to overview]	Pharmacokinetics Parameter : Skin Flux of INCB018424
NCT00820950 (6) [back to overview]	Change in Target Lesion Area Compared to Baseline
NCT00820950 (6) [back to overview]	Number of Participants With Treatment Emergent Adverse Events
NCT00820950 (6) [back to overview]	Pharmacokinetics Parameter : Bioavailability of INCB018424
NCT00820950 (6) [back to overview]	Change in Target Lesion Individual Component Scores for Erythema, Scaling and Thickness Compared to Baseline
NCT00820950 (6) [back to overview]	Change in Target Lesion TOTAL Score (Sum of Erythema + Scaling + Thickness) Compared to Baseline
NCT00875277 (13) [back to overview]	Change in Scaling Compared to Baseline
NCT00875277 (13) [back to overview]	Change in Single Clinical Symptom Score: Erythema, Scaling, Infiltration Compared to Baseline
NCT00875277 (13) [back to overview]	Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline
NCT00875277 (13) [back to overview]	Pathology and Histology by Treatment
NCT00875277 (13) [back to overview]	Ultrasonography: Change in Lesions Thickness From Baseline Measured by Ultrasound
NCT00875277 (13) [back to overview]	Biomarkers by Immunochemistry: Epidermal Proliferation
NCT00875277 (13) [back to overview]	Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1)
NCT00875277 (13) [back to overview]	Pathology and Histology by Treatment: Epidermal Thickness
NCT00875277 (13) [back to overview]	Pathology and Histology by Treatment: Frequency of Neutrophil Abscesses
NCT00875277 (13) [back to overview]	Biomarkers by Immunochemistry
NCT00875277 (13) [back to overview]	Biomarkers by Immunochemistry: Epidermal Differentiation
NCT00875277 (13) [back to overview]	Change in Erythema Compared to Baseline
NCT00875277 (13) [back to overview]	Change in Infiltration Compared to Baseline
NCT01188928 (4) [back to overview]	Mean Percentage Change in PASI From Baseline to Week 8
NCT01188928 (4) [back to overview]	Mean Percentage Change in PASI From Baseline to Week 4
NCT01188928 (4) [back to overview]	Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4
NCT01188928 (4) [back to overview]	Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 8
NCT01347255 (5) [back to overview]	Change From Baseline in Echo-poor Band Thickness at End of Treatment
NCT01347255 (5) [back to overview]	Changes in Total Skin Thickness
NCT01347255 (5) [back to overview]	Changes in Total Clinical Score (TCS) by Visit
NCT01347255 (5) [back to overview]	Change in Clinical Sign Scores
NCT01347255 (5) [back to overview]	Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline
NCT01422434 (4) [back to overview]	Change in mPASI From Baseline to Week 1
NCT01422434 (4) [back to overview]	Change From Baseline in Modified Psoriasis Area and Severity Index (mPASI)
NCT01422434 (4) [back to overview]	Change From Baseline in Target Lesion Assessment
NCT01422434 (4) [back to overview]	Physician's Global Assessment of Psoriasis
NCT01536938 (1) [back to overview]	Subjects With 'Controlled Disease' ('Clear'/'Almost Clear' for Subjects w. at Least Moderate Disease at Baseline, 'Clear' for Subjects With Mild Disease at Baseline) According to the Investigator's Global Assessment (IGA) on the Trunk and Limbs at Week 4.
NCT01707043 (2) [back to overview]	Subjective Subject Preference Survey for the First Treatment Session
NCT01707043 (2) [back to overview]	Subjective Subject Preference Survey for the Second Treatment Session
NCT02749799 (3) [back to overview]	Change in Investigator's Global Assessment Grade
NCT02749799 (3) [back to overview]	Change in Dermatology Life Quality Index (DLQI)
NCT02749799 (3) [back to overview]	Change in Percent Body Surface Area (BSA) Involved.
NCT02858713 (3) [back to overview]	Lattice-System Physician's Global Assessment (LS-PGA)
NCT02858713 (3) [back to overview]	Dermatology Life Quality Index (DLQI)
NCT02858713 (3) [back to overview]	Percentage of Adherent Participants
NCT03101033 (8) [back to overview]	Functional Status Assessed by Oswestry Disability Index
NCT03101033 (8) [back to overview]	Functional Status Assessed by Oswestry Disability Index
NCT03101033 (8) [back to overview]	Functional Status Assessed by Oswestry Disability Index
NCT03101033 (8) [back to overview]	Functional Status Assessed by Oswestry Disability Index
NCT03101033 (8) [back to overview]	Pain Assessed by Visual Analogue Scale
NCT03101033 (8) [back to overview]	Pain Assessed by Visual Analogue Scale
NCT03101033 (8) [back to overview]	Pain Assessed by Visual Analogue Scale
NCT03101033 (8) [back to overview]	Pain Assessed by Visual Analogue Scale
NCT03441789 (6) [back to overview]	Global Improvement in Itch Visual Analogue Scale (VAS) at Week 4,12 and 16
NCT03441789 (6) [back to overview]	Per Cent of Patients With at Least 1-grade Improvement in Physicians Global Assessment (PGA) at Week 4 and Week 12 and Week 16
NCT03441789 (6) [back to overview]	Percent of Subjects With PASI 90 and 100 at Week 16
NCT03441789 (6) [back to overview]	Percent of Subjects With PASI 75 at Week 4 and Week 12
NCT03441789 (6) [back to overview]	Global Percent Improvement in Dermatologic Quality of Life Index (DLQI) at Week 4, 12, and 16
NCT03441789 (6) [back to overview]	Percent of Subjects With a Psoriasis Assessment and Severity Index (PASI) 75 at Week 16
NCT03758365 (2) [back to overview]	Compare Local Tolerability of the MC2-01 Cream With Active Comparators and Vehicle
NCT03758365 (2) [back to overview]	Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle
NCT03848871 (6) [back to overview]	Change in TLSS (Total Lesion Severity Score) From Baseline to Week 2 and Week 4 - Assessment of Scaling
NCT03848871 (6) [back to overview]	Change in TLSS (Total Lesion Severity Score) From Baseline to Week 2 and Week 4 - Assessment of Erythema
NCT03848871 (6) [back to overview]	Change in Physicians Global Assessment (PGA) From Baseline to Week 2 and Week 4
NCT03848871 (6) [back to overview]	Change in Lesion Size From Baseline to Week 2 and Week 4
NCT03848871 (6) [back to overview]	Change in TLSS (Total Lesion Severity Score) From Baseline to Week 2 and Week 4 - Assessment of Induration
NCT03848871 (6) [back to overview]	Change in Body Surface Area (BSA) From Baseline to Week 2 and Week 4

Number of Days Required to Achieve Total Remission

The speed of action, measured as the number of days required to achieve total remission of all signs and symptoms of the disease. (NCT00671528)
Timeframe: Up to 28 days

Intervention	Days (Number)
Quadriderme® Cream	15
Betamethasone Diproprionate and Gentamicin Sulfate Cream	15
Betamethasone Diproprionate Cream	8

Intervention	ng/cm^2/h (Mean)
Part 1 Cohort A: Ruxolitinib 0.5% Cream vs. Vehicle Cream	54.2
Part 1 Cohort B: Ruxolitinib 1.0% Cream Versus Vehicle	151
Part 1 Cohort C: Ruxolitinib 1.5% Cream vs. Vehicle Cream	422
Part 2 Cohort D: Ruxolitinib vs. Calcipotriene (Dovonex®)	363
Part 2 Cohort E: Ruxolitinib vs. Betamethasone Dipropionate (Diprolene® AF)	383

Intervention	cm^2 (Mean)
Cohort A: Vehicle	0.35
Part 1 Cohort A: Ruxolitinib 0.5% Cream vs. Vehicle Cream	1.53
Cohort B: Vehicle	0.45
Cohort B: Ruxolitinib 1.0% Cream Versus Vehicle	-3.18
Cohort C: Vehicle	-4.03
Part 1 Cohort C: Ruxolitinib 1.5% Cream vs. Vehicle Cream	-11.45
Cohort D: INCB18424	-5.22
Part 2 Cohort D: Ruxolitinib vs. Calcipotriene (Dovonex®)	-2.54
Cohort E: INCB18424	1.53
Part 2 Cohort E: Ruxolitinib vs. Betamethasone Dipropionate (Diprolene® AF)	-0.48

Intervention	Scores on a scale (Mean)
	Day 8 - Erythema	Day 8 - Scaling	Day 8 - Thickness	Day 15 - Erythema	Day 15 - Scaling	Day 15 - Thickness	Day 22 - Erythema	Day 22 - Scaling	Day 22 - Thickness	Day 28 - Erythema	Day 28 - Scaling	Day 28 - Thickness	Day 56/ET - Erythema	Day 56/ET - Scaling	Day 56/ET - Thickness
Part 1 Cohort A: Ruxolitinib 0.5% Cream	-0.5	-0.2	-0.7	-0.7	-0.3	-0.3	-1.0	-0.6	-0.6	-0.4	-0.4	-0.2	-0.3	-0.2	-0.3
Part 1 Cohort A: Vehicle Cream	-0.5	-0.2	-0.7	-0.7	-0.3	-0.3	-0.8	-0.4	-0.2	-0.6	-0.2	-0.4	-0.5	-0.2	-0.3
Part 1 Cohort B: Ruxolitinib 1.0% Cream	-1.0	-0.2	-0.3	-1.0	-0.3	-0.3	-1.5	-0.8	-0.5	-1.7	-1.0	-1.0	-0.2	0.7	0.2
Part 1 Cohort B: Vehicle Cream	-0.8	0.0	-0.2	-0.8	-0.2	-0.2	-1.0	-0.5	-0.3	-1.2	-0.7	-0.3	0.0	0.3	0.0
Part 1 Cohort C: Ruxolitinib 1.5% Cream	-1.2	-1.2	-0.8	-1.2	-1.0	-0.8	-1.2	-1.2	-1.2	-1.0	-1.2	-1.5	-0.5	-0.7	-0.8
Part 1 Cohort C: Vehicle Cream	-0.7	-0.7	-0.3	-0.5	-0.7	-0.5	-0.3	-0.5	-0.8	-0.5	-0.5	-1.2	-0.5	-0.7	-0.7
Part 2 Cohort D: Calcipotriene (Dovonex®)	-0.8	-0.6	-0.6	-0.8	-0.4	-0.8	-1.0	-0.6	-0.8	-1.2	-0.8	-1.0	-1.2	-0.7	-1.0
Part 2 Cohort D: INCB18424	-1.2	-0.6	-0.4	-1.0	-0.2	-0.6	-1.8	-0.6	-1.0	-1.4	-0.8	-1.0	-1.0	-0.8	-1.2
Part 2 Cohort E: Betamethasone Dipropionate (Diprolene® AF)	-1.3	-0.8	-0.8	-1.2	-1.2	-0.6	-1.6	-1.0	-0.8	-1.8	-1.2	-1.2	-0.6	-0.4	-0.4
Part 2 Cohort E: INCB18424	-1.0	-0.8	-0.5	-1.0	-0.8	-0.6	-1.4	-0.8	-1.0	-1.2	-0.8	-1.0	0.2	-0.2	0.0

Intervention	Score on Scale (Mean)
	Day 8	Day 15	Day 22	Day 28	Day 56/ET
Part 1 Cohort A: Ruxolitinib 0.5% Cream vs. Vehicle Cream	-1.3	-1.3	-2.2	-1.0	-1.3
Part 1 Cohort A: Vehicle	-1.3	-1.3	-1.4	-1.2	-1.5
Part 1 Cohort B: Ruxolitinib 1.0% Cream vs. Vehicle Cream	-1.7	-2.0	-3.0	-3.8	0.5
Part 1 Cohort B: Vehicle	-1.0	-1.3	-1.8	-2.2	0.5
Part 1 Cohort C: Ruxolitinib 1.5% Cream vs. Vehicle Cream	-3.2	-3.0	-3.5	-3.7	-2.0
Part 1 Cohort C: Vehicle Cream	-1.7	-1.7	-1.7	-2.2	-1.8
Part 2 Cohort D: INCB18424	-2.4	-2.0	-3.6	-3.4	-3.2
Part 2 Cohort D: Ruxolitinib vs. Calcipotriene (Dovonex®)	-2.2	-2.2	-2.6	-3.2	-3.0
Part 2 Cohort E: INCB18424	-2.3	-2.4	-3.2	-3.0	0.0
Part 2 Cohort E: Ruxolitinib vs. Betamethasone Dipropionate (Diprolene® AF)	-2.8	-3.0	-3.4	-4.2	-1.4

Intervention	units on a scale (Mean)
	Visit 5 (Day 4)	Visit 8 (Day 8)	Visit 11 (Day 11)	Visit 14 (Day 15)	Visit 17 (Day 18)	Visit 20 (Day 22)	Visit 23 (Day 25)
Betamethasone Dipropionate Cream	-0.31	-0.88	-1.15	-1.33	-1.56	-1.54	-1.81
Daivobet® Ointment	-0.52	-1.19	-1.92	-2.04	-2.13	-2.19	-2.21
LEO 29102 Cream	-0.13	-0.44	-0.63	-0.73	-0.90	-0.81	-1.17
LEO 29102 Cream Vehicle	-0.17	-0.27	-0.40	-0.52	-0.65	-0.54	-0.75
LEO 29102 Plus Betamethasone Dipropionate	-0.33	-1.17	-1.48	-1.67	-1.83	-1.75	-2.00
LEO 29102 Plus Calcipotriol Cream	-0.21	-0.63	-0.71	-1.00	-1.15	-1.27	-1.46

Intervention	score on a scale (Mean)
	Erythema	Infiltration	Scaliness
Betamethasone Dipropionate Cream	-1.71	-1.46	-1.79
Daivobet® Ointment	-1.88	-2.04	-2.19
LEO 29102 Cream	-0.90	-0.85	-1.29
LEO 29102 Cream Vehicle	-0.42	-0.46	-0.73
LEO 29102 Plus Betamethasone Dipropionate	-1.85	-1.75	-1.96
LEO 29102 Plus Calcipotriol Cream	-1.19	-1.17	-1.60

Intervention	score on a scale (Mean)
	Infiltration of inflammatory cells	Parakeratosis	Stratum Corneum	Stratum Granulosum
Betamethasone Dipropionate Cream	0.17	0.00	0.33	0.17
Daivobet® Ointment	0.67	0.17	0.33	0.17
LEO 29102 Cream	1.52	1.39	1.52	1.04
LEO 29102 Cream Vehicle	1.50	1.67	1.83	1.42
LEO 29102 Plus Betamethasone Dipropionate	0.50	0.00	0.50	0.00
LEO 29102 Plus Calcipotriol Cream	1.53	1.35	1.41	1.00

Intervention	cells/mm^2 (Mean)
LEO 29102 Cream Vehicle	554.1
Betamethasone Dipropionate Cream	19.45
LEO 29102 Cream	443.3
LEO 29102 Plus Calcipotriol Cream	354.3
LEO 29102 Plus Betamethasone Dipropionate	20.50
Daivobet® Ointment	93.49

Intervention	µm (Mean)
LEO 29102 Cream Vehicle	254.6
Betamethasone Dipropionate Cream	73.81
LEO 29102 Cream	187.5
LEO 29102 Plus Calcipotriol Cream	176.4
LEO 29102 Plus Betamethasone Dipropionate	68.48
Daivobet® Ointment	66.90

Intervention	cells/mm^2 (Mean)
LEO 29102 Cream Vehicle	0.14
Betamethasone Dipropionate Cream	0.00
LEO 29102 Cream	0.15
LEO 29102 Plus Calcipotriol Cream	0.17
LEO 29102 Plus Betamethasone Dipropionate	0.00
Daivobet® Ointment	0.05

Intervention	cells/mm^2 (Mean)
	Macrophages: CD163	Dendritic cells CD1a	T-cell biomarker CD3	Angiogenesis: CD31	T-cell biomarker: CD4	T-cell biomarker: CD45RO	Macrophages: CD68	T-cell biomarker: CD8
Betamethasone Dipropionate Cream	197.4	42.14	124.5	216.3	59.17	101.6	120.3	60.05
Daivobet® Ointment	172.9	56.34	143.9	186.6	66.95	218.2	156.8	65.05
LEO 29102 Cream	291.2	229.3	464.2	331.1	246.4	630.1	323.1	220.7
LEO 29102 Cream Vehicle	313.9	233.8	593.8	430.7	284.3	752.0	370.8	280.5
LEO 29102 Plus Betamethasone Dipropionate	178.2	34.31	126.1	184.2	55.56	121.6	142.1	66.35
LEO 29102 Plus Calcipotriol Cream	383.5	244.0	492.7	348.8	239.0	643.6	303.8	253.2

Intervention	%, positive area/total area (Mean)
	Epidermal differentiation: CK10	Epidermal differentiation: CK16
Betamethasone Dipropionate Cream	0.89	0.00
Daivobet® Ointment	0.89	0.00
LEO 29102 Cream	0.77	0.08
LEO 29102 Cream Vehicle	0.76	0.11
LEO 29102 Plus Betamethasone Dipropionate	0.93	0.01
LEO 29102 Plus Calcipotriol Cream	0.75	0.02

Intervention	percentage of change in PASI (Mean)
LEO 80185	-55.8
Betamethasone	-48.6
Calcipotriol	-43.6
Topical Suspension Vehicle	-20.9

Intervention	percentage of change in PASI (Mean)
LEO 80185	-46.4
Betamethasone	-42.7
Calcipotriol	-32.2
Topical Suspension Vehicle	-17.4

Intervention	millimetres (Mean)
LEO 90100 Cutaneous Spray, Ointment	-0.57
LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone	-0.45
LEO 90100 Cutaneous Spray, Ointment, Vehicle	-0.12
Daivobet® Ointment	-0.46

Intervention	millimetres (Mean)
	Day 29	Day 8	Day 15	Day 22
Daivobet® Ointment	-0.62	-0.33	-0.49	-0.59
LEO 90100 Cutaneous Spray, Ointment	-0.81	-0.37	-0.57	-0.68
LEO 90100 Cutaneous Spray, Ointment, Vehicle	-0.23	-0.07	-0.12	-0.18
LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone	-0.66	-0.28	-0.40	-0.59

Intervention	Scores on a scale (Mean)
	Day 4	Day 8	Day 11	Day 15	Day 18	Day 22	Day 25
Daivobet® Ointment	-0.73	-1.96	-2.96	-3.50	-4.52	-4.75	-5.21
LEO 90100 Cutaneous Spray, Ointment	-0.63	-2.08	-3.38	-4.25	-4.85	-5.71	-6.04
LEO 90100 Cutaneous Spray, Ointment, Vehicle	-0.46	-0.42	-0.98	-1.02	-1.33	-1.56	-1.85
LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone	-0.77	-1.83	-2.40	-3.31	-3.83	-4.38	-4.94

Intervention	units on a scale (Mean)
	Erythema (Day 29)	Scaling (Day 29)	Infiltration (Day 29)	Erythema (Day 4)	Scaling (Day 4)	Infiltration (Day 4)	Erythema (Day 8)	Scaling (Day 8)	Infiltration (Day 8)	Erythema (Day 11)	Scaling (Day 11)	Infiltration (Day 11)	Erythema (Day 15)	Scaling (Day 15)	Infiltration (Day 15)	Erythema (Day 18)	Scaling (Day 18)	Infiltration (Day 18)	Erythema (Day 22)	Scaling (Day 22)	Infiltration (Day 22)	Erythema (Day 25)	Scaling (Day 25)	Infiltration (Day 25)
Daivobet® Ointment	-1.50	-2.02	-1.73	-0.33	-0.23	-0.17	-0.67	-0.73	-0.56	-0.83	-1.23	-0.90	-1.04	-1.40	-1.06	-1.35	-1.74	-1.43	-1.44	-1.81	-1.50	-1.56	-1.98	-1.67
LEO 90100 Cutaneous Spray, Ointment	-1.75	-2.13	-2.13	-0.33	-0.17	-0.13	-0.73	-0.75	-0.60	-1.08	-1.29	-1.00	-1.29	-1.65	-1.31	-1.37	-1.87	-1.61	-1.79	-2.06	-1.85	-1.79	-2.15	-2.10
LEO 90100 Cutaneous Spray, Ointment, Vehicle	-0.56	-0.90	-0.42	-0.19	-0.19	-0.08	-0.13	-0.21	-0.08	-0.29	-0.46	-0.23	-0.33	-0.46	-0.23	-0.35	-0.67	-0.30	-0.52	-0.67	-0.38	-0.56	-0.85	-0.44
LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone	-1.44	-2.02	-1.50	-0.33	-0.31	-0.13	-0.60	-0.81	-0.42	-0.75	-1.06	-0.58	-1.06	-1.40	-0.85	-1.20	-1.52	-1.11	-1.29	-1.73	-1.35	-1.44	-1.98	-1.52

Intervention	Scores on a scale (Mean)
LEO 90100 Cutaneous Spray, Ointment	-6.00
LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone	-4.96
LEO 90100 Cutaneous Spray, Ointment, Vehicle	-1.88
Daivobet® Ointment	-5.25

Intervention	percentage of change (Mean)
Dovonex® Ointment	-23.7
LEO 90105 Ointment	-39.1
Rinderon® - DP Ointment	-29.5

betamethasone sodium phosphate

Description

Cross-References

Synonyms (72)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (2)

Protein Targets (12)

Potency Measurements

Ceullar Components (1)

Research

Studies (164)

Market Indicators

Research Demand Index: 62.00

Study Types

Clinical Trials (110)

Trial Overview

Trial Outcomes

Number of Days Required to Achieve Total Remission

"Controlled Disease(i.e., Clear or Almost Clear) According to the Investigator's Global Assessment of Disease Severity at Week 4."

"Controlled Disease(i.e., Clear or Very Mild) According to the Patient's Global Assessment of Disease Severity at Week 4."

Adverse Drug Reactions

Change in Albumin Corrected Serum Calcium From Baseline to End of Treatment

Serum Cortisol Concentration of ≤18 mcg/dL at 30 Minutes After ACTH-challenge at End of Treatment

Change in Urinary Calcium:Creatinine Ratio From Baseline to End of Treatment.

PASI 50 at Week 4.

PASI 75 at Week 4.

Percentage Change in PASI From Baseline to Week 4.

Serum Cortisol Concentration of ≤18 mcg/dL at 30 and 60 Minutes After ACTH-challenge at End of Treatment

Pharmacokinetics Parameter : Skin Flux of INCB018424

Change in Target Lesion Area Compared to Baseline

Number of Participants With Treatment Emergent Adverse Events

Pharmacokinetics Parameter : Bioavailability of INCB018424

Change in Target Lesion Individual Component Scores for Erythema, Scaling and Thickness Compared to Baseline

Change in Target Lesion TOTAL Score (Sum of Erythema + Scaling + Thickness) Compared to Baseline

Change in Scaling Compared to Baseline

Change in Single Clinical Symptom Score: Erythema, Scaling, Infiltration Compared to Baseline

Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline

Pathology and Histology by Treatment

Ultrasonography: Change in Lesions Thickness From Baseline Measured by Ultrasound

Biomarkers by Immunochemistry: Epidermal Proliferation

Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1)

Pathology and Histology by Treatment: Epidermal Thickness

Pathology and Histology by Treatment: Frequency of Neutrophil Abscesses

Biomarkers by Immunochemistry

Biomarkers by Immunochemistry: Epidermal Differentiation

Change in Erythema Compared to Baseline

Change in Infiltration Compared to Baseline

Mean Percentage Change in PASI From Baseline to Week 8

Mean Percentage Change in PASI From Baseline to Week 4

Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4

Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 8

Change From Baseline in Echo-poor Band Thickness at End of Treatment

Changes in Total Skin Thickness

Changes in Total Clinical Score (TCS) by Visit

Change in Clinical Sign Scores

Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline

Change in mPASI From Baseline to Week 1

Change From Baseline in Modified Psoriasis Area and Severity Index (mPASI)

Change From Baseline in Target Lesion Assessment

Physician's Global Assessment of Psoriasis

Subjects With 'Controlled Disease' ('Clear'/'Almost Clear' for Subjects w. at Least Moderate Disease at Baseline, 'Clear' for Subjects With Mild Disease at Baseline) According to the Investigator's Global Assessment (IGA) on the Trunk and Limbs at Week 4.

Subjective Subject Preference Survey for the First Treatment Session

Subjective Subject Preference Survey for the Second Treatment Session

Change in Investigator's Global Assessment Grade

Change in Dermatology Life Quality Index (DLQI)

Change in Percent Body Surface Area (BSA) Involved.

Lattice-System Physician's Global Assessment (LS-PGA)

Dermatology Life Quality Index (DLQI)

Percentage of Adherent Participants

Functional Status Assessed by Oswestry Disability Index

Functional Status Assessed by Oswestry Disability Index

Functional Status Assessed by Oswestry Disability Index

Functional Status Assessed by Oswestry Disability Index

Pain Assessed by Visual Analogue Scale

Pain Assessed by Visual Analogue Scale

Intervention	percentage of change (Mean)
Dovonex® Ointment	-50.5
LEO 90105 Ointment	-64.3
Rinderon® - DP Ointment	-53.6

Intervention	percentage of change (Mean)
Dovonex® Ointment	-57.1
LEO 90105 Ointment	-70.5
Rinderon® - DP Ointment	-58.6

Intervention	participants (Number)
LEO 90100	45
Betamethasone Dipropionate	31
Calcipotriol Aerosol Foam	15

Intervention	units on a scale (Mean)
Taclonex Scalp Suspension First Then Taclonex Ointment	81.1
Taclonex Ointment First, Then Taclonex Scalp Suspension	77.6

Intervention	units on a scale (Mean)
Taclonex Scalp Suspension First Then Taclonex Ointment	78.9
Taclonex Ointment First, Then Taclonex Scalp Suspension	69.4

Intervention	units on a scale (Mean)
	Change from baseline to week 4	Change from baseline to week 8	Change from baseline to week 26
App + Enstilar©	1.86	2.25	1.98
Conventional Instructions + Enstilar©	1.46	2.16	1.80

Intervention	percentage of participants (Number)
App as Intervention + Enstilar©	65
Conventional Instructions + Enstilar©	38

Intervention	units on a scale (Mean)
Epidural Neuroplasty Group	53.85
Transforaminal Steroid Injection Group	57.84

Intervention	units on a scale (Mean)
Epidural Neuroplasty Group	29.11
Transforaminal Steroid Injection Group	35.02

Intervention	units on a scale (Mean)
Epidural Neuroplasty Group	30.52
Transforaminal Steroid Injection Group	46.39